The study of central nervous system (CNS) leukemia has been hampered by the lack of a suitable animal model. We report that severe combined immunodeficiency (SCID) mice invariably develop rapidly progressive fatal CNS leukemia within 3 weeks after intravenous injection of NALM-6 pre-B acute lymphoblastic leukemia (ALL) cells. Colonization of the dura mater and subarachnoid space, usually of the distal spinal cord with occasional extension into the VirchowRobin spaces of blood vessels subjacent to the meninges, followed involvement of bone marrow in the skull, vertebrae, and, occasionally, the appendicular skeleton. Occult ROPHYLACTIC central nervous system (CNS) therapy, which consists of intrathecal chemotherapy with or without high-dose intravenous (IV) methotrexate or cranial/ craniospinal irradiation in conjunction with intrathecal chemotherapy, has reduced the incidence of CNS relapse in patients with acute lymphoblastic leukemia (ALL) to 5% to However, patients who develop a CNS relapse despite prior prophylactic therapy have only a 15% to 45% chance of long-term disease-free survival (DFS).'s','o," The primary cause of treatment failure in these patients is the recurrence of leukemia in the CNS as well as other extramedullary sites and bone marrow (BM).',7,10," Patients who sustain a second CNS relapse have a dismal outcome."." Furthermore, contemporary CNS radiochemotherapy regimens are often associated with prolonged myelosuppression and neurotoxicity."" Therefore, more effective and less toxic CNS prophylaxis and treatment strategies to prevent seeding of leukemia cells from the CNS to other extramedullary sites and BM, along with more effective systemic therapy to prevent reseeding of the CNS with clonogenic leukemia cells, are needed to further improve long-term DFS after a recurrence in the CNS.
ROPHYLACTIC central nervous system (CNS) therapy, which consists of intrathecal chemotherapy with or without high-dose intravenous (IV) methotrexate or cranial/ craniospinal irradiation in conjunction with intrathecal chemotherapy, has reduced the incidence of CNS relapse in patients with acute lymphoblastic leukemia (ALL) to 5% to However, patients who develop a CNS relapse despite prior prophylactic therapy have only a 15% to 45% chance of long-term disease-free survival (DFS).'s','o," The primary cause of treatment failure in these patients is the recurrence of leukemia in the CNS as well as other extramedullary sites and bone marrow (BM).',7,10," Patients who sustain a second CNS relapse have a dismal outcome."." Furthermore, contemporary CNS radiochemotherapy regimens are often associated with prolonged myelosuppression and neurotoxicity."" Therefore, more effective and less toxic CNS prophylaxis and treatment strategies to prevent seeding of leukemia cells from the CNS to other extramedullary sites and BM, along with more effective systemic therapy to prevent reseeding of the CNS with clonogenic leukemia cells, are needed to further improve long-term DFS after a recurrence in the CNS.
Until recently, the study of new therapeutic modalities for CNS leukemia has been hampered by the lack of a suitable model system. Before clinical trials are initiated in patients with CNS leukemia, information regarding an agent's in vivo activity is desirable. Clonogenic assays are useful indicators of the in vitro antileukemic efficacy of new drugs against freshIy isolated primary ALL blasts. However, in vitro clonogenic assays do not provide direct evidence for the in vivo activity of a new agent, nor do they provide an estimate of toxicity. Furthermore, clonogenic assays do not offer an opportunity to evaluate the toxicity and efficacy of multiagent therapeutic regimens. Therefore, we were motivated to establish an in vivo model system of human CNS leukemia.
We and others have used mutant CB.17 mice with severe combined immunodeficiency (SCID) as a model system to examine the in vivo homing, engraftment, and growth patterns of normal and malignant human hematopoietic celis.'2"s In this report, we show that NALM-6 human pre-B ALL cells cause overt and fatal CNS leukemia when injected IV into SCID mice. Intriguingly, histologically detectable engraftment of leukemia cells in skull or vertebral BM and meninges preceded engraftment in other sites. Furthermore, intrathecal CNS therapy with B43 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin, a new anti-ALL agent that does not cross the blood-brain b a r~i e r , '~. '~ was more effective in achieving long-term event-free survival (EFS) than systemic therapy with the same agent, suggesting that seeding of BM and other extramedullary sites by blasts from the CNS plays a major role in progression of leukemia in this model system. The SCID mouse model of human CNS leukemia described in this report is devised to provide a basis for future comparative studies of the toxicity and efficacy of new CNS therapy regimens in B-lineage ALL. A major finding of clinical significance reported here is that leukemic blasts in the CNS can be effectively eradicated by weekly intrathecal administration of B43-PAP immunotoxin without side effects. These experiments provide a paradigm for the critical evaluation of a new CNS therapy regimen in B-lineage ALL.
Cells and inoculation. The previously described human NALM-6-UMI (NALM-6) pre-B ALL cell lineI7 was maintained by serial passage in RPM1 1640 medium (GIBCO Laboratories, Grand Island, NY) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (Hyclone Laboratories, Logan, UT), 50 pg/mL streptomycin, 50 IU/mL penicillin, 2 mmolL L-glutamine, and 10 mmollL HEPES buffer. Cells were cultured in tissue culture flasks at 37°C in a humidified 5% COn atmosphere. Before injection, cells were washed twice in phosphate-buffered saline (PBS) and resuspended in PBS at 2.5 X IO'/mL or S X IO'lmL. Inoculation was into the dorsal tail vein.
Drugs. B43-PAP immunotoxin was produced in the Immunotoxin Production Facility of the University of Minnesota Biotherapy Program, as previously described." Methotrexate (25 mglmL) was obtained from Lederle Parenterals Inc (Carolina, Puerto Rico).
Intrathecal and systemic therapy for xenografed human CNS leukemia. Intrathecal injections were made into the lumbar space using a syringe with a 25-gauge needle, and 20 ng substance P (total volume, 1 pL) was coadministered to confirm the success of the intrathecal injections; substance P induces a caudally directed scratching and biting response when injected into the lumbar space of mice." To evaluate the efficacy of intrathecal therapy with 843-PAP immunotoxin, 6-week-old male SCID mice were inoculated in the dorsal tail vein with 1 X lo6 NALM-6 cells and treated with weekly intrathecal injections of B33-PAP (0.5 pg, I .0 pg, 2.0 pg, 2.5 pg, or 10 p g per dose in IO p L normal saline) on days 14, 21, 28, and 3.5. For comparison, control mice were treated with intrathecal normal saline, methotrexate, or systemic (ie, intraperitoneal) B43-PAP. Intrathecal treatments of 15 pg methotrexate (total injection volume, 10 pL) diluted with normal saline were delivered weekly for 4 weeks according to the same schedule as for intrathecal B43-PAP. Mice were observed daily for evidence of disease and killed when moribund or unable to obtain food or water because of paralysis. Long-term surviving mice were electively killed at 11 I days after inoculation of NALM-6 cells. For each treatment group, at least two mice that died early in the observation period and two mice that died late were histologically examined to assess their CNS and systemic leukemia burden. NALM-6-inoculated, untreated control mice were killed at 14 days postinoculation to assess their leukemia burden at the time of initiation of treatment. After the discovery of drug-related paralysis in SCID mice after intrathecal administration of B43-PAP, single IO-to 75-pg intrathecal doses were administered to Balb/c mice to further characterize the histologic lesions of the spinal cord.
Exatninarion of SCID mouse tissues for xenografted huntan leukemia cells. At the time of death, necropsies were performed, and tissues, including BM and brain, of SCID mice were collected for GUNTHER ET AL evaluation of the human pre-B ALL leukemia burden. Tissues from mice that died or were euthanized by exposure to CO2 gas were fixed with 10% neutral buffered formalin by perfusion via the lef ventricle or by immersion. The axial and appendicular skeleton, containing the CNS and BM, were subsequently decalcified in 10% formic acid for 48 hours. Representative portions of tissues, including multiple sections of all regions of the spinal column, were dehydrated and embedded in paraffin by routine methods. Six-micron. hematoxylin and eosin-stained sections were examined. For immunophenotypic studies, leukemic cells were dissociated from the leptomeninges of the brain by gently vortexing the whole brain in PBS in a test tube. BM suspensions were prepared by flushing the marrow cavities of long bones with PBS using a syringe with a 25-gauge needle. Other tissues were gently homogenized in PBS. Multiparameter flow cytometric analyses using two-color immunofluoreccence staining techniques and pairwise combinations of a selected panel of fluorochrome [fluorescein isothiocyanate (FITC) or phycoerythrin (PE)]-labeled monoclonal antibodies (MoAbs) were performed on the cell suspensions, as previously described.""' The following MoAbs were included in the analyses: B43 (anti-CD19). J-S (anti-CD10; Coulter Corp. Hialeah, FL), Leu-12 (anti-CD19). Leu-16 (anti-CDW), Hle-1 (anti-CD45; Becton-Dickinson, Rutherford, NJ), and anti-lgM p-chain (Tago, Inc, Burlingame, CA).
Human DNA was detected in mouse tissues by amplifying a 1 IO-bp fragment from the first exon of the human P-globin gene using a previously published polymerase chain reaction (PCR) Sfutistical unulyses. Event times were measured from the day of inoculation of NALM-6 cells to the day of paraplegia or death. The probabilities of paraplegia and EFS were determined, and eventfree interval curves were generated using the Kaplan-Meier product limit method, as previously r e p~r t e d . '~"~ The log-rdnk test was used to assess the effects of various treatment protocols on the probability of EFS of SCID mice inoculated with NALM-6 cells.
RESULTS
Human pre-B ALL cell line N A M -6 causes fatul CNS leukemia in SCID mice. Of 83 SCID mice challenged with an IV inoculum of 1 X 10' NALM-6 cells, 83 developed symptomatic CNS leukemia. The first clinical sign of CNS leukemia was a muscle weakness in the rear legs with a slight lowering of the lower back at a median of 32 days (mean ? SE, 33 ? 1 days; range, 26 to 58 days). Subsequently, mice developed a rapidly progressive paralysis of the rear legs, and at a median of 39 days (range, 36 to 56 days), they were no longer able to obtain food or water Groups of three SClD mice were killed o n the indicated days after inoculation with 5 x lo6 NALM-6 cells, and assays were performed as detailed in Materials and Methods. PCR was performed on whole brain without dura mater. Histology of the CNS was performed on sections of the brain and spinal cord.
Abbreviations: PCR, PCR amplification of human 0-globin gene sequences; ND, not done; f, detection by PCR or histopathology in three of three mice; -, absence of leukemic cells by PCR or histopathology in three of three mice.
* First day any animal in a group was positive
For personal use only. on December 25, 2017 . by guest www.bloodjournal.org From because of paralysis. Some of these mice suffered a generalized tonic-clonic seizure followed by sudden death. whereas others either died without a preceding seizure or they were electively killed in moribund condition. Postmortem histopathologic studies showed that the CNS was extensively involved, with dense leukemic cell infiltrates in the subarachnoid space and the superficial perivascular Virchow-Robin spaces (data not shown). Large numbers of CDIO'CDI9'CD20-human NALM-6 leukemia cells could be dissociated from the leptomeninges of the brain by gently vortexing the whole brain of paralyzed SCID mice in PBS in a test tube.
To further study the pathobiology of xenografted human CNS leukemia. SCID mice were inoculated in the dorsal tail vein with S X 10" NALM-6 cells. Mice were observed daily, and groups of three mice were killed on days I , 2. and S and at 3-day intervals from R days to 30 days postinoculation and subjected to pathologic analysis to assess their leukemia burden. Xenografted human leukemia cells were first detected in the BM, always starting in the skull or vertebrae. All mice had histologically detectable BM involvement in the skull or vertebrae and occasionally the appendicular skeleton by day I 1 (Table I ). NALM-6 cells in hematoxylin and eosin-stained sections of paraffin-embedded mouse BM were easily distinguished from murine hematopoietic cells. Leukemic cells were 10-to 13-pm in diameter. with oval to irregularly polygonal nuclei with smooth borders, finely stippled chromatin, and a single prominent eosinophilic nucleolus. They had scant. lightly basophilic cytoplasm and a high mitotic rate. Colonization of the dura mater and subarachnoid space, usually of the distal spinal cord, was observed as early as 20 and 23 days postinoculation, respectively, and colonization of both sites was a constant feature after 23 days (Table I , Fig 1 ) . Histologically evident CNS involvement was limited to the dura mater and subarachnoid space, with occasional extension into the Virchow-Robin spaces of blood vessels subjacent to the meninges: no leukemic cells were seen in the Virchow-Robin spaces of blood vessels deep within the parenchyma of the CNS. The kinetics of engraftment of NALM-6 cells in SClD mouse tissues was also examined by PCR analysis. Groups of three mice were killed on days I. 2, and S and at 3-day intervals from day 8 to day 20. and their occult leukemia burden was evaluated by PCR amplification of human DNA, as described.".'* As shown in Fig 2A. no PCR evidence of occult CNS leukemia was found in SClD mice at 1 to 5 days after inoculation of NALM-6 cells. By contrast, positive control SCID mice that died of disseminated leukemia with CNS involvement showed strong PCR positivity for human @globin gene sequences in DNA specimens from BM and brain (Fig 2B) . Similarly. PCR analysis of SClD mouse BM and brain invariably showed presence of human DNA at 8. 1 l , 14, 17, and 20 days (Fig 2C through E) . Although histologically detectable engraftment of leukemia cells in skull or vertebral BM and meninges preceded engraftment in other sites. PCR analysis of human DNA detected leukemic cell engraftment in extraneural sites (eg. liver) as early as in the CNS and BM (Fig 2C) .
Several features suggest that a major mechanism of colonization of the meninges by NALM Colonization of the endosteum occurred earlier than colonization of the dura mater, and colonization of the dura mater was always accompanied by involvement of the adjacent endosteum. (4) Colonization of the subarachnoid space was always accompanied by involvement of the adiacent dura. whereas the reverse was not always true. ( 5 ) Streams of leukemic cells could be seen entering the CNS from the BM by direct penetration through the cortex. along vascular channels or along nerve roots (Fig 3) .
lntrrrtheccrl R43 (anti-CD1 9)-PAP therap! is cflectiw agrrinst .renogrqfted human CNS leukemia in SClD mice. Occult leukemia of the CNS was shown by PCR analysis of brains at the time of initiation of treatments (14 days after inoculation of I X IOh NALM-6 cells) in four of four SCID mice that were randomly selected at the time of assignment to treatment groups. Histologic examination of the CNS showed leukemic cells in one of six mice at this timepoint. All 23 saline-injected control mice became paralyzed and developed histologically demonstrable CNS and systemic leukemia. Intrathecal administration of methotrexate did not significantly increase survival of the SClD mice, and all I O mice that received intrathecal methotrexate treatment died with extensive CNS leukemia at a median of 49 days ( Table  2 . Fig 4) . Three mice treated with intrathecal injections of unconjugated B43 antibody (2.5 pg per dose) died of leukemia at 46. 52, and S9 days. respectively (data not shown). Similarly, all mice treated with weekly intraperitoneal B43-PAP injections died of disseminated leukemia at a median of 44 days ( Table 2 ). The presence of xenografted NALM-6 cells in BM andor CNS of SCID mice treated with normal saline, intraperitoneal B43-PAP, or intrathecal methotrexate was confirmed by PCR detection of human DNA (Fig SA  and B) . Intrathecal administration of B43-PAP prolonged survival of SClD mice inoculated with NALM-6 leukemia cells (Table 2, Fig 4) . The median survival time of mice administered weekly intrathecal doses of 2.5 pg B43-PAP (ie. 68 days) was significantly greater than the median survival time of the saline control group (ie. 41 days) or the methotrexate-treated group (ie, 49 days: P < .OOOl: Table   2 ). Two mice in the 2.5 pg intrathecal B43-PAP group were in good health at the end of the I I 1 day observation period and had no histologic evidence of leukemia in the CNS or BM. The human DNA contamination in the BM or brain of these mice appeared to be less than 0.001% (Fig SA. C. and  D) . For each of the three intrathecal B43-PAP treatment groups receiving B43-PAP at 1.0. 2.0, or 2.5 pg per dose, four mice that died during the 120-day observation period were evaluated histologically. All 12 mice had disseminated leukemia with CNS involvement.
Systemic administration of B43-PAP does not provide an alternative to intrathecal B43-PAP therapy for xenografted CNS leukemia, as B43-PAP immunotoxin molecules are too large to cross the blood-brain barrier. As shown in Table 2 , intraperitoneal administration of 2.5 pg B43-PAP, given at the same dose schedule as the intrathecal B43-PAP regimen. did not increase survival, indicating that intrathecal administration was the key factor in increasing survival time. Intraperitoneal administration of 20 pg B43-PAP in three equally divided consecutive daily doses on days 14, 1 S , and 16 after inoculation with NALM-6 cells significantly prolonged survival (median survival, 65 days; P < .02), but all mice in this group died with CNS leukemia (Table 2) .
There was no histologic evidence of neurotoxicity in the mice that received intrathecal B43-PAP doses up to 2.5 pg. However. all 10 mice that received intrathecal injections of IO pg B43-PAP developed rear leg paralysis shortly after the onset of treatment (Table 2 ). All but one of these mice only developed signs of neurotoxicity after two or more injections of B43-PAP. All six histologically examined mice in this group had severe damage of the terminal sacral spinal cord (site of injection), characterized by severe necrosis of gray and white matter, as well as degeneration of tracts within the ventral nerve roots of this region (Fig 6) . There were no morphologic lesions of the blood vessels. Neurotoxicity was the cause of paralysis in these mice. as no histologic or PCR evidence of CNS leukemia was found.
DISCUSSION
We report that the SClD mouse microenvironment permits the development of a rapidly progressive and invariably fatal CNS leukemia after inoculation with human NALM-6 pre-B ALL cells via a tail vein. Also provided is experimental evidence that intrathecal B43
(anti-CD I9)-PAP immunotoxin therapy at a nontoxic dose level significantly improves survival of SClD mice with xenografted CNS leukemia.
The first histologic evidence of CNS leukemia in this model is often found in the distal spinal cord. preceding
For and data analysis was performed as described in Materials and Methods. Abbreviations: it, intrathecal; ip, intraperitoneal; qwk, every week.
involvement of the brain. The reason for this predilection is not known, but may be related to inoculation with the NALM-6 cells into the tail vein. There are anastomoses between abdominal veins and vertebral veins in other species, suggesting that these may be avenues of colonization of the CNS.*' Of interest is the finding that one avenue of colonization of the meninges of the brain and spinal cord appears to be direct extension from adjacent BM, as has been suggested by other^.^^,^^ This may not be the consequence of specific tropism of these cells for the CNS, however, as invasion of the adjacent skeletal muscle from the BM also commonly occurred.
PCR amplification detected human DNA in the CNS of
. . the SCID mice before histologically demonstrable proliferation of NALM-6 cells in the adjacent BM, suggesting that colonization of the CNS may also occur by a means other than direct extension from the marrow. These leukemic cells in the CNS may account for the eventual disseminated leukemia in mice treated only by intraperitoneal administration of B43-PAP, as seen in this and a previous study." Intrathecal therapy for occult CNS leukemia with B43-PAP significantly prolonged survival of SCID mice inoculated 14 days previously with 1 X lo6 NALM-6 pre-B ALL cells and resulted in the apparent cure of several mice. Intraperitoneal therapy with B43-PAP (20 pg total dose administered on 3 consecutive days) was not as efficacious as intrathecal therapy, as would be expected from therapy that does not pass the blood-brain barrier. However, it increased survival of SCID mice, suggesting that it eliminated many, if not all, accessible leukemic cells. PCR assay showed that human leukemic cells were present in the CNS of the SCID mice at the initiation of intraperitoneal treatment, suggesting that these cells may be the progenitors of the systemic leukemia found at the time of death in these mice.
----O"-NS
Interestingly, mice treated intrathecally or intraperitoneally with 22.0 pg B43-PAP and that died with leukemia early (less than 45 days) in the course of the study tended to have only leukemic involvement of the spinal cord and adjacent vertebral BM, whereas mice that died later (greater than SO days) had disseminated disease with leukemic involvement of the spinal cord, BM, and viscera. Therefore, we speculate that (1) CNS leukemia causes paralysis that necessitates euthanasia before severe morbidity due to involvement of BM or viscera occurs, and (2) the CNS serves as a source of cells that seed extraneural sites. According to 
D
hypothesis is supported by the fact that in the described SCID model, massive medullary and visceral leukemic burdens did not cause morbidity; neurologic signs of CNS disease were the first clinical evidence for onset of human leukemia. There was no clinical or morphologic evidence of toxicity in mice given four weekly intrathecal treatments with 2.5 pg B43-PAP, a dose level that produced significantly prolonged survival and apparent cure in some SCID mice. However, intrathecal administration of B43-PAP at dose levels 210 pg per weekly single dose caused major damage to the spinal cord. Interestingly, neurotoxicity of intrathecal B43-PAP appeared to be cumulative. Only one mouse became paralyzed after a single intrathecal injection of I O pg, whereas paralysis developed in the others only after multiple weekly injections of 10 pg. Damage only occurred near the site of injection, suggesting that neurotoxicity is caused by high local concentrations of B43-PAP, a situation that might be prevented by slow infusion of a dilute solution of the immunotoxin. This hypothesis can be tested in larger species.
The SCID mouse model of human CNS leukemia described in this report provides a basis for future comparative studies of the toxicity and efficacy of novel CNS therapy regimens in B-lineage ALL. These experiments provide a paradigm for the critical evaluation of a new CNS therapy regimen in B-lineage ALL. This report also extends previous studies that showed the potential therapeutic benefit of inFor personal use only. on December 25, 2017 . by guest www.bloodjournal.org From trathecal immunotoxin therapy against leptomeningeal carcinomatosis."."
